Pomerantz Law Firm Investigates Rafael Holdings Following Failed Phase 3 Clinical Trial
Pomerantz LLP has launched an investigation into Rafael Holdings, Inc. (NYSE: RFL) regarding potential securities fraud or unlawful business practices. The probe follows a significant decline in the company's stock price after its subsidiary, Cyclo Therapeutics, LLC, released disappointing clinical trial results. On September 30, 2026, Rafael announced that its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™ failed to achieve statistical significance on its primary endpoint for treating Niemann-Pick Disease Type C. This news caused the company's share price to plummet by nearly 35%, closing at $1.32 per share.
Tickers: $RFL
Topics: class action lawsuit clinical trial failure securities fraud investigation stock price drop